Skip to main content
. 2016 Mar 18;37(5):522–529. doi: 10.1093/carcin/bgw032

Figure 2.

Figure 2.

Downregulation of RIPK1 expression in head and neck cancer correlates with disease progression. Immunohistochemical analysis of resected primary (n = 90) and lymph node metastatic (n = 32) tumor specimens from patients with HNSCC was performed for RIPK1 expression. A representative H&E stained sample is shown in (A), upper panel. The lower graph shows the quantitation of RIPK1 expression (B) RIPK1 mRNA expression from RNAseq2 data in HNSCC patient paired normal solid tissue and primary solid tumors (n = 30) obtained from The Cancer Genome Atlas. This data was provided as RNA-Seq gene expression estimation with read mapping uncertainty (RSEM) and the RSEM of RIPK1 was normalized to the RSEM of Actin.